Alexander A. Zukiwski - 07 Sep 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc.

Role
EVP and Chief Medical Officer
Signature
/s/Alexander A. Zukiwski
Issuer symbol
N/A
Transactions as of
07 Sep 2022
Net transactions value
$0
Form type
4
Filing time
09 Sep 2022, 16:01:37 UTC
Previous filing
06 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CASI Employee Stock Option (Right to Buy) Award $0 +3,000 $0.000000 3,000 07 Sep 2022 Common Stock 3,000 $15.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 25, 2021, subject to approval at the June 15, 2021 shareholders meeting, the reporting person was granted these stock options that vest upon achievement of certain performance based conditions. The performance based condition was satisfied on September 7, 2022, resulting in vesting of the options.
F2 On June 1, 2022, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split"). The number of stock options and the exercise price reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.